Search filters

Filters
Clear All

Phase

  • 8
  • 10
  • 3
  • 2
  • 24
  • 13
  • 24

Found 24 Small Cell Lung Cancer trials

A listing of Small Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib)  a Third Generation EGFR-TKI  as Monotherapy or in Combinations With JNJ-61186372  a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer
18 years - 99 years
All genders
Phase 1
the purpose of this study is to see if lazertinib and JNJ-61186372 are safe and useful for treating patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC). Eligible subjects will be those with NSCLC.
99 years or below
All genders
Phase 2
The primary purpose of this study is to gain information about the safety and activity of grapiprant when taken with pembrolizumab in patients who have actively growing or spreading type of advanced stage lung cancer called non-small cell lung cancer (NSCLC).
 UPCC 05519: Single-Arm Study Of Carboplatin Weekly Taxane And Ramucirumab In Advanced NSCLC After Progressive Disease On Maintenance Pemetrexed And/Or Pembrolizumab
18 years - 100 years
All genders
Phase 2
The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.Participants for …
 An Open-Label  Safety and Tolerability Phase 1b Trial of CAN04  A Fully Humanized Anti-IL1RAP Monoclonal Antibody  in Combination with Pembrolizumab in Subjects with Solid Tumors Progressing on PD-1/PD-L1 Inhibitor-Containing Regimens
99 years or below
All genders
Phase 1
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer, head and neck squamous cell carcinoma, urothelial cancer, or malignant melanoma. The study aims to establish a recommended dose of CAN04 in combination …
21 - 24 of 24